Literature DB >> 31703948

Cell-free DNA in blood as a noninvasive insight into the sarcoma genome.

Heidi Maria Namløs1, Kjetil Boye2, Leonardo A Meza-Zepeda3.   

Abstract

Sarcomas are malignant tumors of mesenchymal origin that arise mainly from connective and supportive tissue. Sarcomas include a wide range of histological subtypes, showing a large diversity at the molecular level, from simple to highly complex karyotypes but with few recurrent somatic changes. Therapeutic decisions increasingly rely on the molecular characteristics of the individual tumor. Circulating cell-free DNA (ctDNA) is released into peripheral blood and can be used for the genomic analysis of sarcomas. However, the diversity and heterogeneity of somatic changes observed in sarcomas pose a challenge when choosing an adequate assay for the detection of ctDNA in body fluids. In this review, we provide an overview of different studies on ctDNA from blood in bone and soft tissue sarcomas, including gastrointestinal stromal tumors. We will specifically address the technological challenges that must be considered to achieve the sensitive detection of ctDNA and discuss the clinical applications of ctDNA in the management and treatment of sarcomas.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Circulating cell-free DNA; Circulating tumor DNA; GIST; Liquid biopsies; Sarcoma

Mesh:

Substances:

Year:  2019        PMID: 31703948     DOI: 10.1016/j.mam.2019.10.004

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  3 in total

1.  Comparative study on the mutation spectrum of tissue DNA and blood ctDNA in patients with non-small cell lung cancer.

Authors:  Meichun Zhang; Jing Wu; Weinong Zhong; Ziwen Zhao; Weihong Guo
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

Review 2.  Oncogenic Dysregulation of Circulating Noncoding RNAs: Novel Challenges and Opportunities in Sarcoma Diagnosis and Treatment.

Authors:  Lidia Chellini; Ramona Palombo; Veronica Riccioni; Maria Paola Paronetto
Journal:  Cancers (Basel)       Date:  2022-09-26       Impact factor: 6.575

3.  Molecular profiling of soft-tissue sarcomas with FoundationOne® Heme identifies potential targets for sarcoma therapy: a single-centre experience.

Authors:  Susanne Scheipl; Iva Brcic; Tina Moser; Stefan Fischerauer; Jakob Riedl; Marko Bergovec; Maria Smolle; Florian Posch; Armin Gerger; Martin Pichler; Herbert Stoeger; Andreas Leithner; Ellen Heitzer; Bernadette Liegl-Atzwanger; Joanna Szkandera
Journal:  Ther Adv Med Oncol       Date:  2021-07-25       Impact factor: 8.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.